The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.

The present invention in the field of cancer therapeutics is based on the finding that when cannabinoids are administered to cancer subjects after a chemotherapeutic agent has been administered, the combined treatment leads to increased survival prognosis, a reduction in disease progression, stabilisation of disease state and inhibition of tumour growth than administration of the chemotherapeutic agent alone. There is provided a pharmaceutical composition comprising a chemotherapeutic agent for use in the treatment of bladder, brain and spinal cord, colorectal, head and neck, lung, lymphoma, neuroendocrine, oesophageal, ovarian, pancreatic and prostate cancer, wherein said treatment comprises a first phase in which the chemotherapeutic agent is administered, and a subsequent second phase in which a cannabinoid is administered.

The present invention in the field of cancer therapeutics is based on the finding that when cannabinoids are administered to cancer subjects after a chemotherapeutic agent has been administered, the combined treatment leads to increased survival prognosis, a reduction in disease progression, stabilisation of disease state and inhibition of tumour growth than administration of the chemotherapeutic agent alone. There is provided a pharmaceutical composition comprising a chemotherapeutic agent for use in the treatment of bladder, brain and spinal cord, colorectal, head and neck, lung, lymphoma, neuroendocrine, oesophageal, ovarian, pancreatic and prostate cancer, wherein said treatment comprises a first phase in which the chemotherapeutic agent is administered, and a subsequent second phase in which a cannabinoid is administered.

This invention relates to compounds that treat microbial skin infections. Previously, powered forms of talk were difficult to apply to skin without becoming a lung irritant. Embodiments of the present invention use talc, lanolin, petroleum jelly, sodium lauryl ether sulfate, sodium chloride, water, sodium salicylate, Lauryl ether sulfate, Isopropyl palmitate, propylene glycol, mineral oil, and sodium benzoate.

Provided herein are compositions for delivering one or more cannabinoids to the skin of a subject and methods of using the compositions to deliver the one or more cannabinoids to the skin of a subject. The compositions contain a carrier that facilitates the delivery and permeation of cannabinoids to and through the skin. The carriers of the compositions contain squalane or mixtures of squalane and hemisqualane. The compositions described herein may serve as the base for the preparation of various cosmetics or various pharmaceuticals. The cosmetics or pharmaceuticals may be used to reduce inflammation, control pain, or prevent aging of the skin of a subject.

Provided herein are compositions for delivering one or more cannabinoids to the skin of a subject and methods of using the compositions to deliver the one or more cannabinoids to the skin of a subject. The compositions contain a carrier that facilitates the delivery and permeation of cannabinoids to and through the skin. The carriers of the compositions contain squalane or mixtures of squalane and hemisqualane. The compositions described herein may serve as the base for the preparation of various cosmetics or various pharmaceuticals. The cosmetics or pharmaceuticals may be used to reduce inflammation, control pain, or prevent aging of the skin of a subject.

Embodiments of the disclosure encompass methods and compositions for the treatment of medical conditions in which cell regeneration is in need, including neural cells. In specific embodiments, the cell are retinal cells and include Müller glial cells. In particular embodiments, an individual with retinal regeneration is provided an effective amount of one or more histone acetylase inhibitors for the purpose of regenerating retinal cells, including retinal neurons.

Embodiments of the disclosure encompass methods and compositions for the treatment of medical conditions in which cell regeneration is in need, including neural cells. In specific embodiments, the cell are retinal cells and include Müller glial cells. In particular embodiments, an individual with retinal regeneration is provided an effective amount of one or more histone acetylase inhibitors for the purpose of regenerating retinal cells, including retinal neurons.

Personal care compositions for improving the appearance and/or health of skin are provided herein. In accordance with an aspect, provided is a personal care formulation comprising an alpha hydroxy acid; a beta hydroxy acid; and polyhydroxy acid comprising gluconodeltalactone. According to another aspect, a personal care formulation is provided that comprises an alpha hydroxy acid; a beta hydroxy acid; and polyhydroxy acid, wherein the personal care formulation has a weight ratio of alpha hydroxy acid to polyhydroxy acid is about 5:1 to about 1:4, and wherein the personal care formulation has a weight ratio of beta hydroxy acid to polyhydroxy acid is about 1:1 to about 1:11.

Personal care compositions for improving the appearance and/or health of skin are provided herein. In accordance with an aspect, provided is a personal care formulation comprising an alpha hydroxy acid; a beta hydroxy acid; and polyhydroxy acid comprising gluconodeltalactone. According to another aspect, a personal care formulation is provided that comprises an alpha hydroxy acid; a beta hydroxy acid; and polyhydroxy acid, wherein the personal care formulation has a weight ratio of alpha hydroxy acid to polyhydroxy acid is about 5:1 to about 1:4, and wherein the personal care formulation has a weight ratio of beta hydroxy acid to polyhydroxy acid is about 1:1 to about 1:11.